EMA Authorised: Kevzara (sarilumab) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA has authorised Kevzara (sarilumab) for rheumatoid arthritis in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• KEVZARA (sarilumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid. MAH: Sanofi Winthrop Industrie. Decision date: 19/02/2026